SAB's SAB-139 protects non-human primates from Ebola virus infection

SAB Biotherapeutics Inc. (Sioux Falls, S.D.) reported data from 12 rhesus macaques challenged with a lethal dose of Ebola virus showing that SAB-139 given one or three days postinfection conferred 100% protection against Ebola virus infection whereas both untreated control animals died four days after infection. Data were published in The Journal of Infectious Diseases...